Moderna, Inc.
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Strategic collaborations by Quarter
Strategic collaborations — Blackstone Life Sciences (influenza) funding recognized as contra-R&D ($M) ($M)
Moderna Strategic collaborations: $24M in Q2 2026, down 85.0% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Collaboration & Development Funding Note.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Strategic collaborations — Blackstone Life Sciences (influenza) funding recognized as contra-R&D ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 24 | -85.0% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 50 | -44.4% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 66 | -71.6% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 25 | -16.7% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 160 | – | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2025 | Mar 31, 2025 | 90 | – | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 232 | – | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 30 | – | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 0 | – | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 0 | – | Form 10-Q (filed 2025-05-01) ↗ |
Breakdown
What makes up strategic collaborations
Cite this data
StockData. (2026). Moderna Strategic collaborations ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rd-blackstone-flu
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.